Follicular Neutrophilic Inflammation (Hidradenitis Suppurativa)

  • Angelo Valerio MarzanoEmail author
  • Giovanni Damiani
  • Alessandro Borghi


Follicular neutrophilic inflammation or Hidradenitis Suppurativa (HS), also known as acne inversa, is a chronic-relapsing, debilitating inflammatory disease of the hair follicle that usually presents after puberty, affecting apocrine gland-bearing skin, most commonly the axillae, inguinal regions and anogenital area [1]. It is clinically characterized by recurrent, painful, deep-seated nodules commonly ending in abscesses and sinus tracts with suppuration and hypertrophic scarring [1].


  1. 1.
    Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158–64.CrossRefPubMedGoogle Scholar
  2. 2.
    Miller IM, McAndrew RJ, Hamzavi I. Prevalence, risk factors, and comorbidities of hidradenitis suppurativa. Dermatol Clin. 2016;34:7–16.PubMedCrossRefGoogle Scholar
  3. 3.
    Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–44.PubMedCrossRefGoogle Scholar
  4. 4.
    Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422–34.PubMedCrossRefGoogle Scholar
  5. 5.
    Schlapbach C, Hänni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65:790–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Marzano AV, Ceccherini I, Gattorno M, et al. Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine (Baltimore). 2014;93:e187.CrossRefGoogle Scholar
  7. 7.
    Feldmeyer L, Werner S, French LE, Beer HD. Interleukin-1, inflammasomes and the skin. Eur J Cell Biol. 2010;89:638–44.PubMedCrossRefGoogle Scholar
  8. 8.
    Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73(5 Suppl 1):S4–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Derm. 2013;133:97–103.PubMedCrossRefGoogle Scholar
  10. 10.
    Sung S, Kimball AB. Counterpoint: analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;69:818–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68:412–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596–601.PubMedCrossRefGoogle Scholar
  13. 13.
    Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35:191–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Jemec GB. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol. 1988;119:345–50.PubMedCrossRefGoogle Scholar
  15. 15.
    van der Zee HH, Jemec GB. New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes. J Am Acad Dermatol. 2015;73:S23–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Revuz J. Hidradenitis suppurativa. Presse Med. 2010;39:1254–64.PubMedCrossRefGoogle Scholar
  17. 17.
    Canoui-Poitrine F, Le Thuaut A, Revuz JE, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol. 2013;133:1506–11.PubMedCrossRefGoogle Scholar
  18. 18.
    Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)—a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409–15.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013;149:762–4.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Marzano AV, Borghi A, Stadnicki A, et al. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis. 2014;20:213–27.PubMedCrossRefGoogle Scholar
  21. 21.
    Marzano AV, Ramoni S, Caputo R. Amicrobial pustulosis of the folds. Report of 6 cases and a literature review. Dermatology. 2008;216:305–11.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Marzano AV, Tavecchio S, Berti E, et al. Cytokine and chemokine profile in amicrobial pustulosis of the folds: evidence for autoinflammation. Medicine (Baltimore). 2015;94:e2301.CrossRefGoogle Scholar
  23. 23.
    Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigh RRH, editor. Dermatologic surgery. New York: Marcel Dekker; 1989. p. 729–39.Google Scholar
  24. 24.
    Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149:211–3.PubMedCrossRefGoogle Scholar
  25. 25.
    Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161:831–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;18:846–55.CrossRefGoogle Scholar
  27. 27.
    Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205–17.PubMedCrossRefGoogle Scholar
  28. 28.
    Kimball AB, Jemec GB, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171:1434–42.PubMedCrossRefGoogle Scholar
  29. 29.
    Chiricozzi A, Faleri S, Franceschini C, et al. AISI: a new disease severity assessment tool for hidradenitis suppurativa. Wounds. 2010;27:258–64.Google Scholar
  30. 30.
    Smith HS, Chao JD, Teitelbaum J. Painful hidradenitis suppurativa. Clin J Pain. 2010;26:435–44.PubMedCrossRefGoogle Scholar
  31. 31.
    Matusiak L, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol. 2010;62:706–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Wolkenstein P, Loundou A, Barrau K, et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56:621–3.PubMedCrossRefGoogle Scholar
  33. 33.
    Kurek A, Peters EM, Chanwangpong A, et al. Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol. 2012;67:e1.CrossRefGoogle Scholar
  34. 34.
    Gooderham M, Papp K. The psychosocial impact of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73:S19–22.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Wortsman X, Moreno C, Soto R, et al. Ultrasound in-depth characterization and staging of hidradenitis suppurativa. Dermatol Surg. 2013;39:1835–42.CrossRefPubMedGoogle Scholar
  36. 36.
    Wortsman X, Castro A, Figueroa A. Color Doppler ultrasound assessment of morphology and types of fistulous tracts in hidradenitis suppurativa (HS). J Am Acad Dermatol. 2016;75:760–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Zarchi K, Yazdanyar N, Yazdanyar S, et al. Pain and inflammation in hidradenitis suppurativa correspond to morphological changes identified by high-frequency ultrasound. J Eur Acad Dermatol Venereol. 2015;29:527–32.CrossRefPubMedGoogle Scholar
  38. 38.
    Damiani G, Della Valle V, Iannone M, et al. Autoinflammatory Disease Damage Index (ADDI): a possible newborn also in hidradenitis suppurativa daily practice. Ann Rheum Dis. 2017;76(8):e25. pii: annrheumdis-2016-210901.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Kohorst JJ, Kimball AB, Davis MD. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73:S27–35.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Sabat R, Chanwangpong A, Schneider-Burrus S, et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One. 2012;7:e31810.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol. 2014;71:1144–50.PubMedCrossRefGoogle Scholar
  42. 42.
    Kromann CB, Deckers IE, Esmann S, et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014;171:819–24.PubMedCrossRefGoogle Scholar
  43. 43.
    Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinology. 2010;2:9–16.CrossRefGoogle Scholar
  44. 44.
    Egeberg A, Jemec GB, Kimball AB, et al. Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa. J Invest Dermatol. 2017;137(5):1060–4. pii: S0022-202X(17)30011-3018.PubMedCrossRefGoogle Scholar
  45. 45.
    Richette P, Molto A, Viguier M, et al. Hidradenitis suppurativa associated with spondyloarthritis—results from a multicenter national prospective study. J Rheumatol. 2014;41:490–4.CrossRefPubMedGoogle Scholar
  46. 46.
    Marzano AV, Ishak RS, Colombo A, et al. Pyoderma gangrenosum, acne and suppurative hidradenitis syndrome following bowel bypass surgery. Dermatology. 2012;225:215–9.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Lapins J, Ye W, Nyrén O, Emtestam L. Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol. 2001;137:730–4.PubMedGoogle Scholar
  48. 48.
    Meixner D, Schneider S, Krause M, et al. Acne inversa. J Dtsch Dermatol Ges. 2008;6:189–96.PubMedCrossRefGoogle Scholar
  49. 49.
    Verneuil A. Études sur les tumeurs de la peau; des quelques maladies des glandes sudoripares. Arch Gen Med. 1854;IV:447–68.Google Scholar
  50. 50.
    Verneuil A. De l’hidrosadénite phlegmoneuse et des abcés sudoripares. Arch Gén Méd. 1864;2:537–57.Google Scholar
  51. 51.
    Shelley WB, Cahn MM. The pathogenesis of hidradenitis suppurativa in man. Arch Dermatol. 1955;72:562.CrossRefGoogle Scholar
  52. 52.
    Brunsting HA. Hidradenitis suppurativa; abscess of the apocrine sweat glands. Arch Derm Syphilol. 1939;39:108–20.CrossRefGoogle Scholar
  53. 53.
    Brunsting HA. Hidradenitis and other variants of acne. Arch Derm Syphilol. 1952;65:303–15.CrossRefGoogle Scholar
  54. 54.
    Pillsbury DM, Shelley WB, Kligman AM. Bacterial infections of the skin. In: Pillsbury DM, Shelley WB, Kligman AM, editors. Dermatology. 1st ed. Philadelphia: Saunders; 1956. p. 459–98.Google Scholar
  55. 55.
    Plewig G, Kligman AM. Acne morphogenesis and treatment. Berlin: Springer; 1975. p. 192.Google Scholar
  56. 56.
    Yu CC-W, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol. 1990;122:763–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Plewig G, Steger M. Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa). In: Marks R, Plewig G, editors. Acne and related disorders. London: Martin Dunitz; 1989. p. 345–57.Google Scholar
  58. 58.
    Jemec GB, Hansen U. Histology of hidradenitis suppurativa. J Am Acad Dermatol. 1996;34:994–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol. 2015;73:S8–S11.PubMedCrossRefGoogle Scholar
  60. 60.
    Wang B, Yang W, Wen W, et al. Gamma-secretase gene mutations in familial acne inversa. Science. 2010;330:1065.PubMedCrossRefGoogle Scholar
  61. 61.
    Pink AE, Simpson MA, Desai N, et al. Mutations in the gamma-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J Invest Dermatol. 2012;132:2459–61.PubMedCrossRefGoogle Scholar
  62. 62.
    Pink AE, Simpson MA, Brice GW, et al. PSENEN and NCSTN mutations in familial hidradenitis suppurativa (Acne Inversa). J Invest Dermatol. 2011;131:1568–70.PubMedCrossRefGoogle Scholar
  63. 63.
    Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity. 2010;32:14–27.PubMedCrossRefGoogle Scholar
  64. 64.
    Melnik BC, Plewig G. Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology. Exp Dermatol. 2013;22:172–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Gentle ME, Rose A, Bugeon L, et al. Noncanonical notch signaling modulates cytokine responses of dendritic cells to inflammatory stimuli. J Immunol. 2012;189:1274–84.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165:391–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Lima AL, Karl I, Giner T, et al. Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa. Br J Dermatol. 2016;174:514–21.CrossRefPubMedGoogle Scholar
  68. 68.
    Cho KA, Suh JW, Lee KH, et al. IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1b by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int Immunol. 2012;24:147–58.PubMedCrossRefGoogle Scholar
  69. 69.
    Dréno B, Khammari A, Brocard A, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol. 2012;148:182–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Hofmann SC, Saborowski V, Lange S, et al. Expression of innate defense antimicrobial peptides in hidradenitis suppurativa. J Am Acad Dermatol. 2012;66:966–74.PubMedCrossRefGoogle Scholar
  71. 71.
    Hunger RE, Surovy AM, Hassan AS, et al. Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C-type lectin receptor. Br J Dermatol. 2008;158:691–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Schlapbach C, Yawalkar N, Hunger RE. Human beta-defensin-2 and psoriasin are overexpressed in lesions of acne inversa. J Am Acad Dermatol. 2009;61:58–65.PubMedCrossRefGoogle Scholar
  73. 73.
    van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164:1292–8.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Kurayev A, Ashkar H, Saraiya A, Gottlieb AB. Hidradenitis suppurativa: review of the pathogenesis and treatment. J Drugs Dermatol. 2016;15:1017–22.PubMedGoogle Scholar
  75. 75.
    van der Zee HH, Laman JD, de Ruiter L, et al. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol. 2012;166:298–305.PubMedCrossRefGoogle Scholar
  76. 76.
    Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60:539–61.PubMedCrossRefGoogle Scholar
  77. 77.
    Marzano AV, Borghi A, Meroni PL, Cugno M. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016;175:882–91.CrossRefPubMedGoogle Scholar
  78. 78.
    Marzano AV, Menicanti C, Crosti C, Trevisan V. Neutrophilic dermatoses and inflammatory bowel diseases. G Ital Dermatol Venereol. 2013;148:185–96.PubMedGoogle Scholar
  79. 79.
    Marzano A, Damiani G, Ceccherini I, et al. Autoinflammation in pyoderma gangrenosum and its syndromic form PASH. Br J Dermatol. 2016;176(6):1588–98. Scholar
  80. 80.
    Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89:601–3.PubMedCrossRefGoogle Scholar
  81. 81.
    Satoh TK, Mellett M, Contassot E, French LE. Are neutrophilic dermatoses autoinflammatory disorders? Br J Dermatol. 2016. [Epub ahead of print].
  82. 82.
    Nikolakis G, Join-Lambert O, Karagiannidis I, et al. Bacteriology of hidradenitis suppurativa/acne inversa: a review. J Am Acad Dermatol. 2015;73(5 Suppl 1):S12–8.PubMedCrossRefGoogle Scholar
  83. 83.
    Ingram JR, Woo PN, Chua SL, et al. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. Br J Dermatol. 2016;174:970–8.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173:1546–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Alavi A, Kirsner RS. Local wound care and topical management of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73:S55–61.PubMedCrossRefGoogle Scholar
  86. 86.
    Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22:325–8.PubMedCrossRefGoogle Scholar
  87. 87.
    Alhusayen R, Shear NH. Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2015;73:S42–6.PubMedCrossRefGoogle Scholar
  88. 88.
    Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258–65.PubMedCrossRefGoogle Scholar
  89. 89.
    Mendonça CO, Griffiths CE. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol. 2006;154:977–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219:148–54.PubMedCrossRefGoogle Scholar
  91. 91.
    van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219:143–7.PubMedCrossRefGoogle Scholar
  92. 92.
    Bettoli V, Zauli S, Borghi A, et al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol. 2014;28:125–6.PubMedCrossRefGoogle Scholar
  93. 93.
    Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39:971–4.PubMedCrossRefGoogle Scholar
  94. 94.
    Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: a case series of five patients. J Dermatolog Treat. 2006;17:211–3.PubMedCrossRefGoogle Scholar
  95. 95.
    Yazdanyar S, Boer J, Ingvarsson G, et al. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. 2011;222:342–6.PubMedCrossRefGoogle Scholar
  96. 96.
    Hogan DJ, Light MJ. Successful treatment of hidradenitis suppurativa with acitretin. J Am Acad Dermatol. 1988;19:355–6.PubMedCrossRefGoogle Scholar
  97. 97.
    Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol. 2011;164:170–5.PubMedCrossRefGoogle Scholar
  98. 98.
    Matusiak L, Bieniek A, Szepietowski JC. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol. 2014;171:170–4.PubMedCrossRefGoogle Scholar
  99. 99.
    Verdolini R, Simonacci F, Menon S, Pavlou P, Mannello B. Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age. G Ital Dermatol Venereol. 2015;150:155–62.PubMedGoogle Scholar
  100. 100.
    Brocard A, Dreno B. Innate immunity: a crucial target for zinc in the treatment of inflammatory dermatosis. J Eur Acad Dermatol Venereol. 2011;25:1146–52.PubMedCrossRefGoogle Scholar
  101. 101.
    Sawers RS, Randall VA, Ebling FJ. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol. 1986;115:269–74.PubMedCrossRefGoogle Scholar
  102. 102.
    Stellon AJ, Wakeling M. Hidradenitis suppurativa associated with use of oral contraceptives. BMJ. 1989;298:28–9.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Mortimer PS, Dawber RP, Gales MA, et al. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115:263–8.PubMedCrossRefGoogle Scholar
  104. 104.
    Blok JL, van Hattem S, Jonkman MF, Horváth B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168:243–52.PubMedCrossRefGoogle Scholar
  105. 105.
    Lee RA, Eisen DB. Treatment of hidradenitis suppurativa with biologic medications. J Am Acad Dermatol. 2015;73:S82–8.PubMedCrossRefGoogle Scholar
  106. 106.
    Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230:27–33.PubMedCrossRefGoogle Scholar
  107. 107.
    Gisondi P, Girolomoni G. Impact of TNF-α antagonists on the quality of life in selected skin diseases. G Ital Dermatol Venereol. 2013;148:243–8.PubMedGoogle Scholar
  108. 108.
    Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146:501–4.PubMedGoogle Scholar
  109. 109.
    Gulliver WP, Jemec GB, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2012;26:911–4.PubMedCrossRefGoogle Scholar
  110. 110.
    Sharon VR, Garcia MS, Bagheri S, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol. 2012;92:320–1.PubMedCrossRefGoogle Scholar
  111. 111.
    Zarchi K, Dufour DN, Jemec GB. Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Dermatol. 2013;149:1192–4.PubMedCrossRefGoogle Scholar
  112. 112.
    Deckers IE, van der Zee HH, Balak DM, Prens EP. Fumarates, a new treatment option for therapy-resistant hidradenitis suppurativa: a prospective open-label pilot study. Br J Dermatol. 2015;172:828–9.PubMedCrossRefGoogle Scholar
  113. 113.
    Danby FW, Hazen PG, Boer J. New and traditional surgical approaches to hidradenitis suppurativa. J Am Acad Dermatol. 2015;73:S62–5.PubMedCrossRefGoogle Scholar
  114. 114.
    van Hattem S, Spoo JR, Horváth B, et al. Surgical treatment of sinuses by deroofing in hidradenitis suppurativa. Dermatol Surg. 2012;38:494–7.PubMedCrossRefGoogle Scholar
  115. 115.
    Kohorst JJ, Baum CL, Otley CC, et al. Surgical management of hidradenitis suppurativa: outcomes of 590 consecutive patients. Dermatol Surg. 2016;42:1030–40.PubMedCrossRefGoogle Scholar
  116. 116.
    Gulliver W, Zoubolis CC, Prens E, et al. Evidence-based approach to the treatment of hidradentis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17:343–51.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Angelo Valerio Marzano
    • 1
    Email author
  • Giovanni Damiani
    • 1
  • Alessandro Borghi
    • 2
  1. 1.Dipartimento di Fisiopatologia Medico-Chirurgica e dei TrapiantiUniversità degli Studi di Milano, Unità Operativa di Dermatologia, IRCCS Fondazione Ca’ Granda, Ospedale Maggiore PoliclinicoMilanoItaly
  2. 2.Dipartimento di Scienze Mediche, Sezione di Dermatologia e Malattie InfettiveUniversità degli Studi di FerraraFerraraItaly

Personalised recommendations